Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 7/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 0.82 |
| ▸ | BCL2 | P10415 | 2/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | APAF1 | O14727 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | GALK1 | P51570 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | TDP2 | O95551 | 2/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987852 | 1.00 | PTPRC (1.00) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL29689751 | 0.95 | PTPRC (0.91) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL3948979 | 0.95 | PTPRC (0.91) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL824162 | 0.95 | PTPRC (0.91) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL29827415 | 0.95 | PTPRC (0.91) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL391353 | 0.93 | PTPRC (0.87) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL29524280 | 0.91 | PTPRC (0.83) | PTPRCS100A4BCL2MCL1NPC1 | |
| Ammonia Solution, Strong SCHEMBL28061163 | 0.91 | PTPRC (0.83) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL30523603 | 0.91 | PTPRC (0.83) | PTPRCS100A4BCL2MCL1NPC1 | |
| SCHEMBL5273079 | 0.91 | PTPRC (0.83) | PTPRCS100A4BCL2MCL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | claimed |
| JP-2003518085-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| CN-118005661-A | Organic compound, application thereof and organic electroluminescent device using same | 北京鼎材科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-108424344-B | Monomer and polymer containing phenanthrene five-membered ring-fused unit, and preparation method and application thereof | 华南协同创新研究院 | 2021-07-02 | — | — | CN | disclosed |
| US-20180006225-A1 | Compositions with Triarylamine Derivatives and Oled Device Containing the Same | DOW GLOBAL TECHNOLOGIES LLC | 2018-01-04 | — | — | US | disclosed |
| EP-1242363-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0872903-B1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | SHINETSU CHEMICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6277519-B1 | QUENCHING AN ALLOY MELT; COMMINUTION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-6096144-A | TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5858571-A | TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207812-A1 | Cd45 inhibitors | CD74, CD2, PTPRC | PTPRC 3/4885S100A4 2288/4885BCL2 2139/4885 |
| US-20180006225-A1 | Compositions with Triarylamine Derivatives and Oled Device Containing the Same | DRD2, NSD2, DRD4 | PTPRC 4683/4885S100A4 2558/4885BCL2 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.